Carbonic anhydrases II and XII are up-regulated in osteoclast-like cells in advanced human atherosclerotic plaquesTampere Vascular Study

Annals of Medicine

Volumn 42, Issue 5, 2010, Pages 360-370

  Oksala, Niku ^a,b   Levula, Mari ^a   Pelto Huikko, Markku ^a   Kytömïki, Leena ^c   Soini, Juhani T ^c   Salenius, Juha ^b   Kähönen, Mika ^b   Karhunen, Pekka J ^a   Laaksonen, Reijo ^a   Parkkila, Seppo ^d   Lehtimki, Terho ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TURKU CENTRE FOR BIOTECHNOLOGY   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Atherosclerosis; Carbonic anhydrases; Gene expression; Immunohistochemistry

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE XII; CD68 ANTIGEN;

ADULT; AGED; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMORAL ARTERY; GENE EXPRESSION; GIANT CELL; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INTERNAL MAMMARY ARTERY; OSTEOCLAST LIKE CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; UPREGULATION;

ACID PHOSPHATASE; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATHEROSCLEROSIS; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASES; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; GIANT CELLS; HUMANS; ISOENZYMES; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; OSTEOCLASTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 77953550229     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.486408     Document Type: Article

References (63)

1. Doherty TM, Uzui H, Fitzpatrick LA, Tripathi PV, Dunstan CR, Asotra K, et al. Rationale for the role of osteoclast-like cells in arterial calcifcation. FaseB J. 2002;16:577-582
2. Jeziorska M, McCollum C, Wooley DE. Observations on bone formation and remodelling in advanced atherosclerotic lesions of human carotid arteries. Virchows arch. 1998;433:559-565
3. Schmid K, Mcsharry WO, Pameijer CH, Binette JP. Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. Atherosclerosis. 1980;37: 199-210.
4. Detrano RC, Doherty TM, Davies MJ, Stary HC. Predicting coronary events with coronary calcium: pathophysiologic and clinical problems. Curr Probl Cardiol. 2000;25: 374-402.
5. Stary HC. Natural history of calcium deposits in atherosclerosis progression and regression. Z kardiol. 2000;89 suppl 2:28-35.
6. Schinke T, Mckee MD, Karsenty G. Extracellular matrix cal-cifcation: where is the action? Nat Genet. 1999;21:150-151
7. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003;423:349-355
8. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342
9. Riihonen R, Supuran CT, Parkkila S, Pastorekova S, Vaananen HK, Laitala-leinonen T. Membrane-bound carbonic anhydrases in osteoclasts. Bone. 2007;40:1021-1031
10. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arte-rioscler thromb vasc Biol. 2001;21:1998-2003.
11. Luo G, Ducy P, Mckee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcifcation of arteries and cartilage in mice lacking matrix Gla protein. Nature. 1997;386: 78-81.
12. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin invest. 1993;91: 1800-1809
13. Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Golden M, Khalapyan T, et al. Bone formation in carotid plaques: a clinicopathological study. Stroke. 2002;33:1214-1219
14. Khosla S. Minireview: the OPG/raNkl/raNk system. Endocrinology. 2001;142:5050-5055
15. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-defcient mice develop early onset osteoporosis and arterial calcifcation. Genes Dev. 1998;12:1260-1268
16. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNFalpha potently activates osteoclasts, Through a direct action independent of and strongly synergistic with raNkl. Endocrinology. 2002;143:1108-1118
17. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, Therapeutic applications and future prospects. J enzyme inhib Med Chem. 2004; 19:199-229.
18. Hilvo M, Tolvanen M, Clark A, Shen B, Shah GN, Waheed A, et al. Characterization of Ca XV, a new GPi-anchored form of carbonic anhydrase. Biochem J. 2005;392(Pt 1):83-92.
19. Halmi P, Lehtonen J, Waheed A, Sly WS, Parkkila S. Expression of hypoxia-inducible, Membrane-bound carbonic anhy-drase isozyme Xii in mouse tissues. Anat rec a Discov Mol Cell evol Biol. 2004;277:171-177
20. Gamble W. Atherosclerosis: the carbonic anhydrase, Carbon dioxide, Calcium concerted theory. J theor Biol. 2006;239:16-21.
21. Oksala N, Levula M, Airla N, Pelto-Huikko M, Ortiz RM, Jarvinen O, et al. ADaM-9, aDaM-15, and aDaM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries\tampere vascular study. Ann Med. 2009;41:279-290
22. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W JR, et al. A defnition of advanced types of atherosclerotic lesions and a histological classifcation of atherosclerosis. A report from the Committee on vascular lesions of the Council on arteriosclerosis, American Heart association. Circulation. 1995;92:1355-1374
23. Laaksonen R, Katajamaa M, Paiva H, Sysi-aho M, Saarinen L, Junni P, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. Plos ONe. 2006;1:e97.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCr and the 2(-Delta Delta C(t)) Method. Methods. 2001;25:402-408
25. Parkkila AK, Parkkila S, Juvonen T, Rajaniemi H. Carbonic anhydrase isoenzymes ii and i are present in the zona glomerulosa cells of the human adrenal gland. Histochem-istry. 1993;99:37-41.
26. Karhumaa P, Parkkila S, Tureci O, Waheed A, Grubb JH, Shah G, et al. Identifcation of carbonic anhydrase Xii as the membrane isozyme expressed in the normal human endometrial epithelium. Mol Hum reprod. 2000;6:68-74. (Pubitemid 30043591)
27. Toyosawa S, Ogawa Y, Chang CK, Hong SS, Yagi T, Kuwahara H, et al. Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme ii in osteoclast-like giant cells in bone tumours. Virchows arch a Pathol anat Histopathol. 1991;418:255-261
28. Hayman AR. Tartrate-resistant acid phosphatase (traP) and the osteoclast/immune cell dichotomy. Autoimmunity. 2008;41:218-223
29. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK. Tartrate-resistant acid phosphatase 5b (traCP 5b) as a marker of bone resorption. Clin lab. 2006;52:499-509.
30. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fxed, Paraffn-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991;39:741-748
31. Rettenmier CW, Sacca R, Furman WL, Roussel MF, Holt JT, Nienhuis AW, et al. Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarci-noma cell lines. J Clin invest. 1986;77:1740-1746
32. Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CsF-1. Cell. 1985;41:665-676
33. Sherr CJ, Rettenmier CW, Roussel MF. Macrophage colony-stimulating factor, CsF-1, and its proto-oncogene-encoded receptor. Cold spring Harb symp Quant Biol. 1988;53 Pt 1:521-530
34. Segovia-silvestre T, Neutzsky-Wulff AV, Sorensen MG, Christiansen C, Bollerslev J, Karsdal MA, et al. Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet. 2009;124:561-577
35. Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, et al. Characterization of osteoclast precursors in human blood. Br J Haematol. 2000;111:501-512
36. Samee N, Geoffroy V, Marty C, Schiltz C, Vieux-rochas M, Levi G, et al. Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. Am J Pathol. 2008;173:773-780
37. Steitz SA, Speer MY, Mckee MD, Liaw L, Almeida M, Yang H, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcifcation. Am J Pathol. 2002;161:2035-2046
38. Athanasou NA, Quinn JM. Human tumour-associated mac-rophages are capable of bone resorption. Br J Cancer. 1992;65:523-526
39. Athanasou NA, Quinn J. Immunophenotypic differences between osteoclasts and macrophage polykaryons: immuno-histological distinction and implications for osteoclast ontogeny and function. J Clin Pathol. 1990;43:997-1003.
40. Athanasou NA, Alvarez JI, Ross FP, Quinn JM, Teitelbaum SL. Species differences in the immunophenotype of osteo-clasts and mononuclear phagocytes. Calcif tissue int. 1992;50:427-432
41. Da Costa CE, Annels NE, Faaij CM, Forsyth RG, Hogen-doorn PC, Egeler RM. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of langerhans cell histiocytosis. J exp Med. 2005;201:687-693
42. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered wound healing in mice lacking a functional oste-opontin gene (spp1). J Clin invest. 1998;101:1468-1478
43. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcifcation in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin invest. 1994;94: 1597-1604
44. Korhonen K, Parkkila AK, Helen P, Valimaki R, Pastore-kova S, Pastorek J, et al. Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase ii with aggressive tumor features. J Neurosurg. 2009;111: 472-477
45. Haapasalo J, Nordfors K, Jarvela S, Bragge H, Rantala I, Parkkila AK, et al. Carbonic anhydrase ii in the endothelium of glial tumors: a potential target for therapy. Neuro Oncol. 2007;9:308-313
46. Leppilampi M, Koistinen P, Savolainen ER, Hannuksela J, Parkkila AK, Niemela O, et al. The expression of carbonic anhydrase ii in hematological malignancies. Clin Cancer res. 2002;8:2240-2245
47. Haapasalo J, Hilvo M, Nordfors K, Haapasalo H, Parkkila S, Hyrskyluoto A, et al. Identifcation of an alternatively spliced isoform of carbonic anhydrase Xii in diffusely infltrating astrocytic gliomas. Neuro Oncol. 2008;10:131-138
48. Hynninen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivela J, Pastorekova S, et al. Expression of transmembrane carbonic anhydrases iX and Xii in ovarian tumours. Histopathology. 2006;49:594-602. (Pubitemid 44924291)
49. Tureci O, Sahin U, Vollmar E, Siemer S, Gottert E, Seitz G, et al. Human carbonic anhydrase Xii: cDNa cloning, Expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl acad sci u s A. 1998;95:7608-7613
50. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504-1508
51. Lehenkari P, Hentunen TA, Laitala-leinonen T, Tuukkanen J, Vaananen HK. Carbonic anhydrase ii plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2 +. Exp Cell res. 1998;242:128-137
52. Laitala T, Vaananen HK. Inhibition of bone resorption in vitro by antisense rNa and DNa molecules targeted against carbonic anhydrase ii or two subunits of vacuolar H(+)-atPase. J Clin invest. 1994;93:2311-2318
53. Sundquist KT, Vaananen HK, Marks sC JR. Carbonic anhydrase ii and H+-atPase in osteoclasts of four osteopetrotic mutations in the rat. Histochem Cell Biol. 1999;111:55-60.
54. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins s and k in human atheroma and regulation of their production in smooth muscle cells. J Clin invest. 1998;102:576-583
55. Collin-Osdoby P. Regulation of vascular calcifcation by osteoclast regulatory factors raNkl and osteoprotegerin. Circ res. 2004;95:1046-1057
56. Guzel O, Innocenti A, Scozzafava A, Salman A, Parkkila S, Hilvo M, et al. Carbonic anhydrase inhibitors: synthesis and inhibition studies against mammalian isoforms i-Xv with a series of 2-(hydrazinocarbonyl)-3-substituted- phenyl-1H-indole-5-sulfonamides. Bioorg Med Chem. 2008;16: 9113-9120
57. Innocenti A, Scozzafava A, Parkkila S, Puccetti L, De simone G, Supuran CT. Investigations of the esterase, Phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and Xiii with 4-nitrophenyl esters as substrates. Bioorg Med Chem lett. 2008;18:2267-2271
58. Dogne JM, Thiry A, Supuran CT. Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs. Curr Pharm Des. 2008;14:679-684
59. Knudsen JF, Carlsson U, Hammarstrom P, Sokol GH, Cantilena LR. The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II. Infammation. 2004;28:285-290
60. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004;47:550-557
61. Di Fiore A, Pedone C, D'ambrosio K, Scozzafava A, De simone G, Supuran CT. Carbonic anhydrase inhibitors: val-decoxib binds to a different active site region of the human isoform ii as compared to the structurally related cyclooxy-genase ii 'selective' inhibitor celecoxib. Bioorg Med Chem lett. 2006;16:437-442
62. Katagiri M, Ogasawara T, Hoshi K, Chikazu D, Kimoto A, Noguchi M, et al. Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II. J Bone Miner res. 2006;21:219-227
63. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959 (Pubitemid 33010342)